Cheetah Medical said it raised an initial $5 million investment from HighCape Partners for its non-invasive hemodynamic monitoring system.
Newton, Mass.-based Cheetah said the round is an extension of a prior raise that brought in $9 million.
"We believe that our technology has the potential to bring significant value to clinicians and other healthcare providers in the ICU, operating room and emergency department by driving fundamental improvements in patient monitoring. This additional capital will fund the continued expansion of our sales and marketing activities in the U.S. and internationally. We are grateful for the continued support of our investors and excited to add HighCape to that list," president & CEO Chris Hutchison said in prepared remarks.
Hutchison, a Covidien (NYSE:COV) veteran, was tapped last year to lead Cheetah, which announced the hire alongside a $14.5 million funding round.
Fletcher Spaght Ventures led the $9 million round announced earlier this year, joined by Springfield Investment Management, MVM Life Science Partners, Robert Bosch Venture Capital and Ascension Health Ventures.
